C1 Esterase Inhibitor

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Kidney TransplantSubarachnoid HemorrhageHereditary Angioedema

476 competitors in Kidney Transplant

#DrugCompanyPhaseTrials

1

Nulojix

Bristol-Myers Squibb

Preclinical

162

Medrol

Pfizer

Preclinical

123

Zinbryta

Roche

Preclinical

64

Cysteine Hydrochloride

Novartis

Preclinical

15

Sensipar

Amgen

Preclinical

16

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

17

Radicava

Shionogi

Preclinical

18

C1 Esterase Inhibitor

Takeda

Phase 2

19

Jardiance

Boehringer Ingelheim

Preclinical

310

Nydrazid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

2Show 20 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Hereditary Angioedema8 trials

Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks

Completed·CSL Behring·Phase 2/3·NCT00168103·126 enrolled

C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)

Completed·CSL Behring·Phase 3·NCT00292981·57 enrolled

A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

Completed·CSL Behring·Phase 3·NCT02316353·126 enrolled

Show 5 more trials

Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks

Completed·Takeda·Phase 3·NCT00462709·146 enrolled

C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks

Completed·Takeda·Phase 3·NCT00289211·83 enrolled

C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks

Completed·Takeda·Phase 3·NCT01005888·26 enrolled

Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects

Completed·Takeda·Phase 1·NCT00432510·27 enrolled

Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks

Completed·Takeda·Phase 3·NCT00438815·113 enrolled

Immune Response2 trials

In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia - VECTOR II

Completed·RRadboud University Medical Center·Phase 3·NCT01766414·20 enrolled

In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia

Completed·RRadboud University Medical Center·N/A·NCT00785018·20 enrolled

Kidney Transplant1 trial

C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI

Completed·—·Phase 1/2·NCT02134314·70 enrolled

Systemic Inflammation1 trial

Effect of C1-esterase Inhibitor on Systemic Inflammation in Trauma Patients With a Femur or Pelvic Fracture

Terminated·UUMC Utrecht·Phase 3·NCT01275976·11 enrolled

Rejection1 trial

Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection

Completed·—·Phase 1/2·NCT01134510·20 enrolled

4 more indications

Intravenous Administration1 trial

Berinert P Study of Subcutaneous Versus Intravenous Administration

Completed·JJohann Wolfgang Goethe University Hospital·Phase 3·NCT00748202·24 enrolled

Renal Transplant Recipients1 trial

Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients

Terminated·CSL Behring·Phase 3·NCT03221842·63 enrolled

Subarachnoid Hemorrhage1 trial

Complement Inhibition: Attacking the Overshooting Inflammation @Fter Subarachnoid Hemorrhage (CIAO@SAH)

Recruiting·HHaaglanden Medical Centre·Phase 2·NCT06359782·128 enrolled

Antibody-mediated Rejection1 trial

A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection

Completed·Takeda·Phase 2·NCT01147302·18 enrolled

Details

Drug Info

Related News